Scholarlink

<p>Photothermal therapy (PTT) is recognized for its precise manipulability and exceptional spatiotemporal control but faces challenges such as thermotolerance, weak penetration, and collateral tissue damage. Herein, we presented a strategy that enabled tumor-targeted PTT, reduced interstitial fluid pressure (IFP), promoted deep tumor penetration, enhanced radiosensitization, and counteracted thermoresistance. An engineered bacteria-based delivery system (R.S@BiOI) responsive to low-dose X-ray was constructed <i>via</i> electrostatic adsorption of bismuth oxyiodide quantum dots (BiOI QDs) onto the natural photothermal agent Rhodobacter sphaeroides (R.S). Leveraging the hypoxic targeting capability of R.S, R.S@BiOI facilitated tumor-specific enrichment and penetration. Meanwhile, X-ray-triggered radiolysis of water by surface-bound BiOI QDs generated hydroxyl radicals, which reduced tumor IFP, enhanced the deep and uniform distribution of the R.S@BiOI composite, and minimized collateral thermal damage to surrounding healthy tissues. Furthermore, X-ray irradiation downregulated the expression of heat shock proteins, attenuating cellular thermotolerance and synergistically improving the efficacy of PTT. Meanwhile, R.S@BiOI elicited a robust anti-tumor immune response, which acted in synergy with radiotherapy and PTT to potentiate the overall antitumor efficacy. The bacteria-based delivery system enhanced intratumoral accumulation and improved tumor distribution, resulting in markedly superior tumor growth suppression, prolonged survival in animal models, and a well-tolerated safety profile with no significant systemic toxicity observed in critical organs. Thus, this study presents a strategy for fabricating X-ray-responsive engineered bacteria that potentiate the therapeutic efficacy of PTT in the treatment of prostate cancer.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

An X-ray-activated nano-bio hybrid for synergistic radiotherapy/photothermal/immunotherapy of prostate cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月1日

查看全文
  • Yizhao Xu,
  • Tao Zhao,
  • Zixuan Li,
  • Jiale Chen,
  • Xin Li,
  • Xiaomei Zhou,
  • Mouna Khouchani,
  • Takoui Abdelmajid,
  • Zhiqiang Jiang,
  • Long Zhao,
  • Zhanlin Zhang

摘要

Photothermal therapy (PTT) is recognized for its precise manipulability and exceptional spatiotemporal control but faces challenges such as thermotolerance, weak penetration, and collateral tissue damage. Herein, we presented a strategy that enabled tumor-targeted PTT, reduced interstitial fluid pressure (IFP), promoted deep tumor penetration, enhanced radiosensitization, and counteracted thermoresistance. An engineered bacteria-based delivery system (R.S@BiOI) responsive to low-dose X-ray was constructed via electrostatic adsorption of bismuth oxyiodide quantum dots (BiOI QDs) onto the natural photothermal agent Rhodobacter sphaeroides (R.S). Leveraging the hypoxic targeting capability of R.S, R.S@BiOI facilitated tumor-specific enrichment and penetration. Meanwhile, X-ray-triggered radiolysis of water by surface-bound BiOI QDs generated hydroxyl radicals, which reduced tumor IFP, enhanced the deep and uniform distribution of the R.S@BiOI composite, and minimized collateral thermal damage to surrounding healthy tissues. Furthermore, X-ray irradiation downregulated the expression of heat shock proteins, attenuating cellular thermotolerance and synergistically improving the efficacy of PTT. Meanwhile, R.S@BiOI elicited a robust anti-tumor immune response, which acted in synergy with radiotherapy and PTT to potentiate the overall antitumor efficacy. The bacteria-based delivery system enhanced intratumoral accumulation and improved tumor distribution, resulting in markedly superior tumor growth suppression, prolonged survival in animal models, and a well-tolerated safety profile with no significant systemic toxicity observed in critical organs. Thus, this study presents a strategy for fabricating X-ray-responsive engineered bacteria that potentiate the therapeutic efficacy of PTT in the treatment of prostate cancer.

Graphical abstract